In the 73–10 assay, 24 of 61 patients (39.3%) had PD-L1-positive tumor cells, while 36 of 61 patients (59.0%) demonstrated CD155 and/or PD-L1 expression in tumor cells. This evidence concerns the gene CD274 and neoplasm.